Skip to content

Clinical trials

Observational Brain Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Brain Neoplasms Phase: Observational Country / region: United States Clear all

188 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20038
20049
20057
20066
20073
200811
20099
20107
20113
20127
20135
201412
201510
201610
201712
20181
20198
20208
20217
20228
20235
20247
20254
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed103
Recruiting27
Terminated23
Active, not recruiting12
Unknown status9
Withdrawn9
Not yet recruiting3
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)21
M.D. Anderson Cancer Center13
National Institute of Neurological Disorders and Stroke (NINDS)10
St. Jude Children's Research Hospital10
Duke University8
Memorial Sloan Kettering Cancer Center8
Mayo Clinic6
Massachusetts General Hospital4
University of Florida4
Monteris Medical3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Brain Neoplasms188
Glioma32
Glioblastoma26
Neoplasms26
Central Nervous System Neoplasms25
Lung Neoplasms19
Breast Neoplasms16
Astrocytoma15
Leukemia11
Head and Neck Neoplasms10

Trials

Showing 1 to 25 of 188. Each trial links to its page on Pharma Observatory.

88 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.